Filter...

AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureHumanitiesInformation ScienceHealth Care

Select a category...

Rats, ZuckerEnalaprilObesityThinnessPeriodicals as TopicJournal Impact FactorBody WeightInsulinPharmacologyPharmacology, ClinicalInsulin ResistanceAngiotensin-Converting Enzyme InhibitorsBlood GlucosePublishingRats, Mutant StrainsEatingBibliometricsMuscle, SkeletalJournalism, MedicalPhysical Conditioning, AnimalAdipose TissueOrgan SizeBlood PressurePyridoxamineGlucosePeer Review, ResearchDisease Models, AnimalKidneyAuthorshipTriglyceridesLiverHypoglycemic AgentsThiazolidinedionesLosartanMonosaccharide Transport ProteinsThiazolesAntihypertensive Agents2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineGlucose Tolerance TestReceptors, LeptinHyperinsulinismGlucose Transporter Type 4Kidney CortexHydrazinesAdipose Tissue, BrownThioctic AcidLipid MetabolismFatty Acids, NonesterifiedRNA, MessengerLeptinTetrazolesReceptor, Angiotensin, Type 2Fatty AcidsMuscle ProteinsHypertensionRenin-Angiotensin SystemAngiotensin IIGlycogenDatabases, BibliographicAngiotensin II Type 1 Receptor BlockersVasodilationReninDose-Response Relationship, DrugFeeding BehaviorPublicationsMetabolic Syndrome XAbstracting and Indexing as TopicRetroperitoneal SpaceMicrocirculationImidazolesDiabetes Mellitus, Type 2LipidsVasoconstrictor AgentsNeuropeptide YKidney GlomerulusExtravascular Lung WaterVasoconstrictionWeight GainBibliography as TopicDehydroepiandrosteroneEsterificationTime FactorsNatriuresisPeer ReviewVasodilator AgentsReference ValuesArteriolesReceptors, Dopamine D1Biomedical ResearchOxidative StressCyclic N-OxidesRats, Sprague-DawleyFatty Acid SynthasesEnalaprilatProteinuriaParaventricular Hypothalamic NucleusLipoprotein LipaseKidney Tubules, ProximalOxygen ConsumptionReceptor, Angiotensin, Type 1

Significantly reduced bloodVehicle-treatedHypertensionExhibitSimilarTherapy

Significantly reduced blood2

• Three-week treatment of SHRs with rosiglitazone and/or enalapril significantly reduced blood pressure, insulin resistance, fasting insulin, and ET-1 levels and increased adiponectin levels to values comparable with those observed in vehicle-treated WKY controls. (diabetesjournals.org)
• In combination, S-Amlodipine and Pioglitazone significantly reduced blood glucose (115.1 ± 6.6 vs. 81.7 ± 4.2), BP (184.4 ± 5.0 vs. 155.1 ± 5.0), serum triglycerides (362.5 ± 47.5 vs. 211.1 ± 23.7) and glucose intolerance when compared with vehicle treated Zucker fa/fa rats. (biomedcentral.com)

Vehicle-treated1

• When compared with WKY control rats, 12-week-old vehicle-treated SHRs were hypertensive, overweight, and insulin resistant, with elevated fasting levels of insulin and ET-1 and reduced serum adiponectin levels. (diabetesjournals.org)

Hypertension1

• Treatment of SHRs with rosiglitazone (insulin sensitizer) and/or enalapril (ACE inhibitor) may simultaneously improve hypertension, insulin resistance, and endothelial dysfunction by rebalancing insulin-stimulated production of vasoactive mediators. (diabetesjournals.org)

Exhibit2

• Despite the anticipated deleterious effects of obesity on cardiovascular outcomes, several studies have revealed that in specific clinical settings, obese patients with advanced IHD exhibit reduced morbidity and mortality compared to disease-matched lean patients. (biomedcentral.com)
• Spontaneously hypertensive rats (SHRs) exhibit endothelial dysfunction and insulin resistance. (diabetesjournals.org)

Similar2

• In isolated, pressurized (80 mmHg) coronary arterioles of obese and non-obese patient the active (73±4 vs. 79±13 μm) and passive (111 ± 5.5 vs. 118 ± 5.0 μm) diameters were similar. (biomedcentral.com)
• Bradykinin elicited substantial dilation in coronary arterioles, with a similar magnitude in obese and non-obese patients (to 10 -8 M: 55 ± 5% vs. 46 ± 5%, P = 0.20), but with significantly enhanced sensitivity in obesity (EC50: 8.2x10 -9 M vs. 1.9x10 -8 M, respectively, P = 0.03). (biomedcentral.com)

Therapy2

• Moreover, obese patients with or without statin exhibited significantly increased coronary dilation to bradykinin, when compared to non-obese patients without statin therapy. (biomedcentral.com)
• By restoring phosphatidylinositol 3-kinase-dependent effects, rosiglitazone and/or enalapril therapy of SHRs also significantly improved vasodilator responses to insulin in MVB preconstricted with NE ex vivo. (diabetesjournals.org)